Results 11 to 20 of about 46,906 (308)

Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial

Emergency, 2016
Introduction: Treatment of rapid ventricular response arterial fibrillation (rapid AF) varies depending on the decision of the in-charge physician, condition of the patient, availability of the drug, and the treatment protocol of the hospital.
Majid Shojaee, Bahareh Feizi, Reza Miri, Jalil Etemadi, Amir Hossein Feizi   +4 more
doaj   +1 more source

Failure of diltiazem to prevent 1:1 conduction of atrial flutter: a case report

Journal of Medical Case Reports, 2023
Background Atrial flutter with 1:1 conduction to the ventricles is a dangerous cardiac arrhythmia. Contemporary guidelines recommend atrioventricular nodal blocking agents should be co-administered with class 1C anti-arrhythmics, as prophylaxis against 1:
K. D. Tiver, D. K. Martin, J. Quah, A. Lahiri, A. N. Ganesan   +4 more
doaj   +1 more source

Selecting patients with nonischemic dilated cardiomyopathy for ICDs [PDF]

, 2017
No abstract ...
Cleland, John G.F., Halliday, Brian P., Prasad, Sanjay K.   +2 more
core   +1 more source

Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database [PDF]

, 2013
Background: Drug-induced torsades de pointes (TdP) and related clinical entities represent a current regulatory and clinical burden. Objective: As part of the FP7 ARITMO (Arrhythmogenic Potential of Drugs) project, we explored the publicly available US ...
A Bate, A Clarke, A Pariente, AK Chung, Ariola Koci, B Darpo, BJ Drew, C Meyer-Massetti, DM Roden, DW Hough, E Poluzzi, E Poluzzi, E Poluzzi, E Raschi, E Raschi, Edoardo Spina, Elijah R. Behr, Elisabetta Poluzzi, Emanuel Raschi, EP Puijenbroek van, ER Behr, F Ponti De, F Ponti De, F Rani, Fabrizio De Ponti, GC Alexander, GK Isbister, H Verdoux, J Nielsen, J Papay, K Jolly, K Titier, LC Wittkampf, LS Schneider, Miriam Sturkenboom, NP Tatonetti, P Kannankeril, P Manu, P Vigneault, RC Owens Jr, RR Shah, S Dhillon, S Hennessy, S Kongsamut, S Leucht, SM Straus, Ugo Moretti, W Crumb, W Crumb, WA Ray, WA Ray, WJ Crumb Jr, WP Stephenson, Y Suzuki   +53 more
core   +4 more sources

Intravenous Amiodarone versus Digoxin in Atrial Fibrillation Rate Control; a Clinical Trial

Archives of Academic Emergency Medicine, 2017
Introduction: Treatment of rapid ventricular response arterial fibrillation (rapid AF) varies depending on the decision of the in-charge physician, condition of the patient, availability of the drug, and the treatment protocol of the hospital.
Majid Shojaee, Bahareh Feizi, Reza Miri, Jalil Etemadi, Amir Hossein Feizi   +4 more
doaj   +1 more source

Chronic beta-adrenoceptor blockade and human atrial cell electrophysiology: evidence of pharmacological remodelling [PDF]

, 2003
<b>Objective:</b> Chronic beta-adrenoceptor antagonist (β-blocker) treatment reduces the incidence of reversion to AF in patients, possibly via an adaptive myocardial response.
Kane, K.A., Norrie, J., Rankin, A.C., Russell, J.A., Workman, A.J.   +4 more
core   +1 more source

Ventricular Arrhythmias in First Acute Myocardial Infarction: Epidemiology, Mechanisms, and Interventions in Large Animal Models

Frontiers in Cardiovascular Medicine, 2019
Ventricular arrhythmia and subsequent sudden cardiac death (SCD) due to acute myocardial infarction (AMI) is one of the most frequent causes of death in humans.
Stefan Michael Sattler, Stefan Michael Sattler, Lasse Skibsbye, Dominik Linz, Dominik Linz, Anniek Frederike Lubberding, Jacob Tfelt-Hansen, Jacob Tfelt-Hansen, Thomas Jespersen   +8 more
doaj   +1 more source

Efficacy of pimobendan in the prevention of congestive heart failure or sudden death in doberman pinschers with preclinical dilated cardiomyopathy (the PROTECT study) [PDF]

, 2012
<p>Background: The benefit of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in Dobermans is not reported.</p> <p>Hypothesis: That chronic oral administration of pimobendan to Dobermans with ...
Boswood, A., Braz-Ruivo, L., Culshaw, G.J., Dukes-McEwan, J., Estrada, A., French, A.T., Gordon, S.G., Loureiro, J., O'Grady, M.R., O'Sullivan, M.L., Oyama, M.A., Patteson, M., Smith, A., Summerfield, N.T., Watson, P.J., Willis, R.   +15 more
core   +3 more sources

Gap junction reduction in cardiomyocytes following transforming growth factor- beta treatment and Trypanosoma cruzi infection [PDF]

, 2009
Gap junction connexin-43 (Cx43) molecules are responsible for electrical impulse conduction in the heart and are affected by transforming growth factor-beta (TGF-beta).
Becker, D, Burnstock, G, Coutinho-Silva, R, de Araujo-Jorge, TC, Feige, JJ, Higuchi, MD, Waghabi, MC   +6 more
core   +2 more sources

A multicenter retrospective cohort study on predicting the risk for amiodarone pulmonary toxicity

BMC Pulmonary Medicine, 2022
Background Amiodarone is one of the most commonly used anti-arrhythmic agents. Amiodarone pulmonary toxicity is a potentially fatal adverse effect associated with amiodarone use.
Wang Chun Kwok, Ting Fung Ma, Johnny Wai Man Chan, Herbert H. Pang, James Chung Man Ho   +4 more
doaj   +1 more source